Easton Pharma of Chengdu Partners with Germany's XL-protein

Easton Pharma of Chengdu entered into a deal with Germany's XL-protein GmbH that calls for XL-protein to develop long-acting biopharma products for unmet needs in ophthalmology. XL-protein will use its proprietary PASylation ® technology for drug half-life extension initially for one Easton target, which was not disclosed. The German company will be responsible for preclinical development activities, while Easton will develop, make and market the PASylated compound. More details.... Share this with colleagues: // //